Traws Pharma GAAP EPS of -$0.11, revenue of $2.73M

* Traws Pharma press release [https://seekingalpha.com/pr/20200744-traws-pharma-reports-second-quarter-2025-results-and-business-highlights] (NASDAQ:TRAW [https://seekingalpha.com/symbol/TRAW]): Q2 GAAP EPS of -$0.11.
* Revenue of $2.73M (vs. $0.057M Y/Y).
* Cash, cash equivalents and short-term investments: As of June 30, 2025, the Company had cash, cash equivalents, and short-term investments of approximately $13.1 million, compared to approximately $21.3 million as of December 31, 2024.

MORE ON TRAWS PHARMA

* Traws Pharma advances antiviral pipeline with multiple regulatory submissions [https://seekingalpha.com/news/4463564-traws-pharma-advances-antiviral-pipeline-with-multiple-regulatory-submissions]
* Financial information for Traws Pharma [https://seekingalpha.com/symbol/TRAW/income-statement]